228 related articles for article (PubMed ID: 19689267)
1. Advances in development of phosphatidylinositol 3-kinase inhibitors.
Kong D; Yamori T
Curr Med Chem; 2009; 16(22):2839-54. PubMed ID: 19689267
[TBL] [Abstract][Full Text] [Related]
2. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.
Zhao W; Qiu Y; Kong D
Acta Pharm Sin B; 2017 Jan; 7(1):27-37. PubMed ID: 28119806
[TBL] [Abstract][Full Text] [Related]
3. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
5. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.
Rewcastle GW; Kolekar S; Buchanan CM; Gamage SA; Giddens AC; Tsang KY; Kendall JD; Singh R; Lee WJ; Smith GC; Han W; Matthews DJ; Denny WA; Shepherd PR; Jamieson SMF
Oncotarget; 2017 Jul; 8(29):47725-47740. PubMed ID: 28537878
[TBL] [Abstract][Full Text] [Related]
6. Structural Determinants of Isoform Selectivity in PI3K Inhibitors.
Miller MS; Thompson PE; Gabelli SB
Biomolecules; 2019 Feb; 9(3):. PubMed ID: 30813656
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
Kong D; Yamori T
Cancer Sci; 2008 Sep; 99(9):1734-40. PubMed ID: 18616528
[TBL] [Abstract][Full Text] [Related]
8. Development of highly sensitive cell-based AKT kinase ELISA for monitoring PI3K beta activity and compound efficacy.
Yanamandra M; Kole L; Giri A; Mitra S
J Immunoassay Immunochem; 2017; 38(6):663-674. PubMed ID: 29035165
[TBL] [Abstract][Full Text] [Related]
9. Development of an immunohistochemical protein quantification system in conjunction with tissue microarray technology for identifying predictive biomarkers for phosphatidylinositol 3-kinase inhibitors.
Isoyama S; Yoshimi H; Dan S; Okamura M; Seki M; Irimura T; Yamori T
Biol Pharm Bull; 2012; 35(9):1607-13. PubMed ID: 22975517
[TBL] [Abstract][Full Text] [Related]
10. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Kong D; Dan S; Yamazaki K; Yamori T
Eur J Cancer; 2010 Apr; 46(6):1111-21. PubMed ID: 20129775
[TBL] [Abstract][Full Text] [Related]
11. PI3K inhibitors for cancer therapy: what has been achieved so far?
Wu P; Liu T; Hu Y
Curr Med Chem; 2009; 16(8):916-30. PubMed ID: 19275602
[TBL] [Abstract][Full Text] [Related]
12. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
13. PI3 kinase inhibitors in the clinic: an update.
Kurtz JE; Ray-Coquard I
Anticancer Res; 2012 Jul; 32(7):2463-70. PubMed ID: 22753702
[TBL] [Abstract][Full Text] [Related]
14. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
Lonetti A; Cappellini A; Spartà AM; Chiarini F; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; McCubrey JA; Martelli AM
Oncotarget; 2015 Apr; 6(12):10399-414. PubMed ID: 25871383
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors.
Sabbah DA; Hu J; Zhong HA
Curr Top Med Chem; 2016; 16(13):1413-26. PubMed ID: 26369826
[TBL] [Abstract][Full Text] [Related]
16. INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.
Reed DE; Shokat KM
Mol Cancer Res; 2017 Jun; 15(6):765-775. PubMed ID: 28196852
[TBL] [Abstract][Full Text] [Related]
17. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
[TBL] [Abstract][Full Text] [Related]
18. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Wang X; Ding J; Meng LH
Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
[TBL] [Abstract][Full Text] [Related]
19. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
[TBL] [Abstract][Full Text] [Related]
20. Targeting phosphoinositide 3-kinase: moving towards therapy.
Marone R; Cmiljanovic V; Giese B; Wymann MP
Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
